RESUMO
A unique dermatopathology incident arose after administration of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine. Specifically, a transient purpuric interface dermatitis occurred 5 days post-second vaccine with the presentation of erythematous papules with erythema multiforme-type findings. A patient developed purpuric interface dermatitis with micro-vesiculation post-vaccination which ultimately resolved without sequelae.
Assuntos
Vacinas contra COVID-19 , Eritema Multiforme , Humanos , Eritema Multiforme/induzido quimicamente , Eritema Multiforme/patologia , Vacinas contra COVID-19/efeitos adversos , Vacina de mRNA-1273 contra 2019-nCoV/efeitos adversos , Feminino , Toxidermias/etiologia , Toxidermias/patologia , Masculino , COVID-19/prevenção & controle , Pessoa de Meia-Idade , Púrpura/etiologia , Púrpura/patologiaRESUMO
BACKGROUND: Progestogen hypersensitivity (PH) is a rare phenomenon reported in women with an immunologic response to rising progesterone levels in the luteal phase. This disease's rarity and clinical spectrum make it challenging to diagnose. CASE: In this case report, we will discuss a 14-year-old female with monthly oral mucositis and palmar lesions consistent with erythema multiforme. Over 2 years, she underwent an extensive multidisciplinary workup and was trialed on many different medical therapies. SUMMARY AND CONCLUSION: The prevalence of PH has grown in the literature over the past decade. Due to progesterone's role in many biochemical pathways, the pathophysiology is complex. Although many modalities are efficacious for treating PH's cyclical eruptions, we propose treatment with a Janus kinase inhibitor when hormonal management alone is insufficient.
Assuntos
Eritema Multiforme , Inibidores de Janus Quinases , Progesterona , Humanos , Feminino , Eritema Multiforme/induzido quimicamente , Eritema Multiforme/tratamento farmacológico , Adolescente , Inibidores de Janus Quinases/uso terapêutico , Inibidores de Janus Quinases/efeitos adversos , Progesterona/efeitos adversos , Estomatite/induzido quimicamente , Estomatite/tratamento farmacológico , RecidivaRESUMO
Erythema multiforme (EM) is an immune-mediated, mucocutaneous hypersensitivity syndrome that can occur as a result of various medications, including a wide range of antineoplastic and hormonal drugs. Anastrozole, a nonselective aromatase inhibitor used in breast cancer management has been associated with different cutaneous side effects, of which EM is rarely seen and usually in a minor or major form with typical target lesions. This is a short report of a patient who developed a rare cutaneous side effect after the use of aromatase inhibitor anastrozole - segmental erythema multiforme in cancer-affected area. Cutaneous adverse effects limited to cancer-affected breast are extremely rare but should be considered in everyday dermatological practice. We find this case instructive not only because of the rarity of the segmental EM, but also because, contrary to classical teaching, drug eruption due to anastrozole occurred months, not days after the initiation of therapy.
Assuntos
Neoplasias da Mama , Toxidermias , Eritema Multiforme , Humanos , Feminino , Anastrozol/efeitos adversos , Inibidores da Aromatase/efeitos adversos , Eritema Multiforme/induzido quimicamente , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/induzido quimicamente , Neoplasias da Mama/complicações , Toxidermias/etiologiaRESUMO
RATIONALE: Dermatologic toxicity has been reported as the most common immune-related side effect of programmed cell death 1 inhibitors. Previous reports related to Sintilimab include rash, pruritus, vitiligo, Stevens-Johnson syndrome, toxic epidermal necrolysis, and so on. PATIENT CONCERNS: A 66-year-old man was treated with Sintilimab as monotherapy for sigmoid colon cancer. After the second prescription, he developed a more severe and widespread rash. DIAGNOSES: The diagnose of erythema multiforme drug eruption induced by Sintilimab was considered. INTERVENTIONS: The patient received intravenous and oral methylprednisolone, routine antihistamines and topical gluccorticoids. OUTCOMES: The patient's symptoms were gradually relieved during hospitalization and was discharged following resolution of symptoms. He refused to continue using Sintilimab. LESSONS: This is the first reported case of Sintilimab-induced erythema multiforme drug eruption. It is advisable to inform patients of potential dermatologic toxicity that may occur after using immune checkpoint inhibitors, so that we may prevent the further development of it and avoid the discontinuation of immune checkpoint inhibitors.
Assuntos
Eritema Multiforme , Exantema , Neoplasias do Colo Sigmoide , Síndrome de Stevens-Johnson , Masculino , Humanos , Idoso , Neoplasias do Colo Sigmoide/complicações , Inibidores de Checkpoint Imunológico , Eritema Multiforme/induzido quimicamente , Eritema Multiforme/diagnóstico , Síndrome de Stevens-Johnson/etiologia , Exantema/induzido quimicamente , Exantema/complicaçõesRESUMO
Regorafenib improves the survival of patients with metastatic colorectal cancer (mCRC); however, it is also characterized by detrimental dermal side effects that may require treatment cessation or modified dosing. In our previous prospective pharmacokinetic, pharmacodynamic, and pharmacogenetic studies, 17.5% (7/40) of the patients with mCRC had grade 3 erythema multiforme (EM) that caused treatment discontinuation. Haplotypes in genes encoding human leukocyte antigen (HLA) are associated with EM following the administration of drugs, such as allopurinol. This study examined the association between HLA haplotypes and regorafenib-induced EM. Regorafenib was administered orally at 160 mg/body once daily for weeks 1-3 of each 4-week cycle. To determine the HLA haplotypes, we used the WAKFlow HLA Typing Kit HLA-A, -B, or -C. The carrier frequency of HLA-C*01:02 in patients with EM (6/7) was higher than that in tolerant controls (8/33; odds ratio [OR] = 18.8, 95% confidence interval [CI] = 1.95-180, p = 0.00437). HLA-B*46:01 was also associated with EM (OR = 11.6, 95% CI = 1.47-92.1, p = 0.0299). These associations were no longer significant after Bonferroni correction for multiple testing. Therefore, regorafenib-induced EM in Japanese patients appears to be associated with specific HLA haplotypes but further validation is needed.
Assuntos
Antineoplásicos , Neoplasias Colorretais , Eritema Multiforme , Humanos , Neoplasias Colorretais/tratamento farmacológico , Neoplasias Colorretais/patologia , População do Leste Asiático , Eritema Multiforme/induzido quimicamente , Eritema Multiforme/genética , Antígenos HLA-B/genética , Antígenos HLA-C/genética , Antineoplásicos/efeitos adversosRESUMO
BACKGROUND: Since the 2002 SCAR study, erythema multiforme (EM), a post-infectious disease, has been distinguished from Stevens-Johnson syndrome (SJS), drug-induced. Nevertheless, EM cases are still reported in the French pharmacovigilance database (FPDB). OBJECTIVES: To describe EM reported in the FPDB and to compare the quality and the characteristics of the reports. METHODS: This retrospective observational study selected all EM cases reported in the FPDB over two periods: period 1 (P1, 2008-2009) and period 2 (P2, 2018-2019). Inclusion criteria were 1) a diagnosis of clinically typical EM and/or validated by a dermatologist; 2) a reported date of onset of the reaction; and 3) a precise chronology of drug exposure. Cases were classified confirmed EM (typical acral target lesions and/or validation by a dermatologist) and possible EM (not-otherwise-specified target lesions, isolated mucosal involvement, doubtful with SJS). We concluded possible drug-induced EM when EM was confirmed, with onset ranging from 5 to 28 days without an alternative cause. RESULTS: Among 182 selected reports, 140 (77%) were analyzed. Of these, 67 (48%) presented a more likely alternative diagnosis than EM. Of the 73 reports of EM cases finally included (P1, n=41; P2, n=32), 36 (49%) had a probable non-drug cause and 28 (38%) were associated with only drugs with an onset time ≤4 days and/or ≥29 days. Possible drug-induced EM was retained in 9 cases (6% of evaluable reports). Etiological work-up was more often performed in period 2 than 1 (53.1% vs 29.3%, P=0.04), and the time to onset from 5 to 28 days was more frequent in period 2 (59.2% vs 40%, P=0.04). CONCLUSIONS: This study suggests that possible drug-induced EM is rare. Many reports describe "polymorphic" rashes inappropriately concluded as EM or post-infectious EM with unsuitable drug accountability subject to protopathic bias.
Assuntos
Eritema Multiforme , Síndrome de Stevens-Johnson , Humanos , Farmacovigilância , Eritema Multiforme/induzido quimicamente , Eritema Multiforme/epidemiologia , Eritema Multiforme/complicações , Síndrome de Stevens-Johnson/epidemiologia , Síndrome de Stevens-Johnson/etiologia , Síndrome de Stevens-Johnson/diagnóstico , Estudos RetrospectivosAssuntos
Artrite Reumatoide , Colite Ulcerativa , Eritema Multiforme , Inibidores de Janus Quinases , Humanos , Colite Ulcerativa/tratamento farmacológico , Colite Ulcerativa/induzido quimicamente , Fator de Necrose Tumoral alfa , Inibidores de Janus Quinases/efeitos adversos , Artrite Reumatoide/tratamento farmacológico , Eritema Multiforme/induzido quimicamente , Eritema Multiforme/diagnóstico , Eritema Multiforme/tratamento farmacológico , Fatores Imunológicos/efeitos adversosRESUMO
RATIONALE: 5-Fluorouracil (5-FU) and actinomycin D (ActD) are often used in chemotherapy for various cancers. Side effects are more common in bone marrow suppression, liver function impairment, and gastrointestinal responses. Skin effects are rare and easy to be ignored by doctors and patients, which can lead to life-threatening consequence. PATIENT CONCERNS: We reported a 45-year-old woman patient developed skin erythema and fingernail belt in chemotherapy of 5-FU and ActD. DIAGNOSIS: Erythema multiforme drug eruption. INTERVENTIONS: Laboratory tests including blood and urine routine, liver and kidney function, electrolytes and coagulation function and close observation. OUTCOMES: The rash was gone and the nail change returned. LESSONS: Delays in diagnosis or treatment may lead to serious consequence. We should pay attention to the dosage of 5-FU and ActD, monitor adverse reactions strictly, to reduce occurrence of skin malignant events.
Assuntos
Toxidermias , Eritema Multiforme , Mola Hidatiforme Invasiva , Neoplasias Uterinas , Feminino , Gravidez , Humanos , Pessoa de Meia-Idade , Dactinomicina/efeitos adversos , Fluoruracila/efeitos adversos , Eritema Multiforme/induzido quimicamente , Toxidermias/etiologiaRESUMO
A 66-year-old Japanese woman had been diagnosed with a neuroendocrine tumor of the pancreatic head (G2) 3 years previously and undergone pancreaticoduodenectomy. Nine months postoperatively, recurrence with multiple liver metastases developed and she was referred to our department. A regimen of 10 mg of everolimus for 2 weeks plus 1-week washout was instituted, and no adverse events were observed. Fourteen months after treatment initiation, she developed severe generalized erythema multiforme (EM). Skin biopsy revealed spongiosis in the epidermis and interface change and edema in the superficial dermis. Mast cells were observed from the dermis to the subcutaneous tissue, as well as perivascular eosinophilic infiltration, leading to EM being diagnosed. Oral everolimus was discontinued, and the EM was relieved by treatment including steroid therapy. Everolimus is an inhibitor of the mammalian target of rapamycin, and its indications include neuroendocrine tumors. Skin disorders are commonly seen in the early stages of everolimus treatment, but their severity is almost always mild and never severe. This is the first report on a patient who presented with severe generalized EM more than 1 year after everolimus treatment initiation. Patients on everolimus therapy should be monitored for skin disorders on a long-term basis.